ePRO For Early Phase Studies: 3 Ways To Benefit

Melissa Newara, Senior Director, Subject Matter Expertise

A new frontier in clinical trial design is emerging as drug development progresses and the competition is fierce. Now more than ever, it is crucial to be first to market. Simultaneously, the importance of incorporating patient-centricity into clinical trials is also growing as participant expectations change.

For the U.S. Food and Drug Administration, bringing the patient’s voice into drug development and evaluation is a key priority. With Patient Reported Outcomes, clinical studies are able to capture myriad outcomes directly from participants, without interpretation by clinicians, that would typically be excluded from traditional clinical trial endpoints. However, not all methods of PRO collection are created equal, and the path a clinical trial team chooses to venture during the early phases will have lasting repercussions as the study progress.

Discover how harnessing ePRO in early-phase trials can boost patient centricity, create more cost-effective operations, and help generate better data faster.